Literature DB >> 8998073

Absence of p53 mutations in malignant mesotheliomas.

O Mor1, P Yaron, M Huszar, A Yellin, O Jakobovitz, F Brok-Simoni, G Rechavi, N Reichert.   

Abstract

Mutations in the p53 gene are the most common genetic alterations found in human malignancies. In this study, a search was done for mutations in the conserved regions of the p53 gene in malignant mesotheliomas. Thirteen malignant mesotheliomas collected over the preceding 12 yr and maintained in paraffin blocks were examined by polymerase chain reaction (PCR) followed by both single-strand conformation polymorphism (SSCP) and denaturing gradient-gel electrophoresis (DGGE). Direct sequence analysis was performed in cases suspected for mutations. No mutations in exons 5 to 8 of the p53 gene were detected. Our results suggest that malignant transformation of human mesothelioma cells does not require inactivation of p53 by point mutations in the conserved regions of the gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8998073     DOI: 10.1165/ajrcmb.16.1.8998073

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  11 in total

Review 1.  Asbestos, Simian virus 40 and malignant mesothelioma.

Authors:  S C Stenton
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

2.  Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Authors:  Gavin J Gordon; Graham N Rockwell; Roderick V Jensen; James G Rheinwald; Jonathan N Glickman; Joshua P Aronson; Brian J Pottorf; Matthew D Nitz; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

3.  Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing.

Authors:  Nao Oumi; Hiroaki Itamochi; Hiroaki Komatsu; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Tasuku Harada
Journal:  Hum Cell       Date:  2015-06-13       Impact factor: 4.174

4.  Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas.

Authors:  F G Mayall; G Jacobson; R Wilkins
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

5.  Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.

Authors:  A Baldi; A M Groeger; V Esposito; R Cassandro; G Tonini; T Battista; M P Di Marino; B Vincenzi; M Santini; A Angelini; R Rossiello; F Baldi; M G Paggi
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

6.  Genomics of Tumor Origin and Characteristics for Adenocarcinoma and Malignant Pleural Mesothelioma: A Case Report.

Authors:  Katsuo Usuda; Yo Niida; Masahito Ishikawa; Shun Iwai; Aika Yamagata; Yoshihito Iijima; Nozomu Motono; Sohsuke Yamada; Hidetaka Uramoto
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

7.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

8.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

9.  Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.

Authors:  Antonella Muscella; Carla Vetrugno; Luca Giulio Cossa; Giovanna Antonaci; Amilcare Barca; Sandra Angelica De Pascali; Francesco Paolo Fanizzi; Santo Marsigliante
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

10.  MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.

Authors:  Giulia Pasello; Loredana Urso; Manlio Mencoboni; Federica Grosso; Giovanni Luca Ceresoli; Francesca Lunardi; Stefania Edith Vuljan; Roberta Bertorelle; Valeria Sacchetto; Vincenzo Ciminale; Federico Rea; Adolfo Favaretto; PierFranco Conte; Fiorella Calabrese
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.